Market revenue in 2018 | USD 29.6 million |
Market revenue in 2027 | USD 49.8 million |
Growth rate | 6% (CAGR from 2018 to 2027) |
Largest segment | High dose rate (hdr) |
Fastest growing segment | High Dose Rate (HDR) |
Historical data covered | 2015 - 2017 |
Base year for estimation | 2018 |
Forecast period covered | 2019 - 2027 |
Quantitative units | Revenue in USD million |
Market segmentation | High Dose Rate (HDR), Low Dose Rate (LDR) |
Key market players worldwide | Eckert & Ziegler Bebig SA, Elekta AB ADR, Siemens Healthineers AG ADR, Icad Inc, Hologic Inc, Merit Medical Systems Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to breast cancer brachytherapy market will help companies and investors design strategic landscapes.
High dose rate (hdr) was the largest segment with a revenue share of 66.22% in 2018. Horizon Databook has segmented the North America breast cancer brachytherapy market based on high dose rate (hdr), low dose rate (ldr) covering the revenue growth of each sub-segment from 2015 to 2027.
Horizon Databook provides a detailed overview of continent-level data and insights on the North America breast cancer brachytherapy market, including forecasts for subscribers. This continent databook contains high-level insights into North America breast cancer brachytherapy market from 2015 to 2027, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account